Prevalence and Prognostic Significance of HPV in Laryngeal Squamous Cell Carcinoma in Northeast China

• Main Authors: Fangjia Tong, Jingshu Geng, Bingqing Yan, Huihuang Lou, Xiaohang Chen, Chenwei Duan, Jing He, Siwei Zhang, Huanhuan Xie, Huining Li, Dawei Yuan, Fengmin Zhang, Hongxue Meng, Lanlan Wei
• Format: Article
• Language: English
• Published: Cell Physiol Biochem Press GmbH & Co KG 2018-08-01
• Series: Cellular Physiology and Biochemistry
• Subjects: Human papillomavirus; Laryngeal squamous cell carcinomas; P16; Prognosis; Overall survival
• Online Access: https://www.karger.com/Article/FullText/492858
• ISSN: 1015-8987; 1421-9778

Background/Aims: Human papillomavirus (HPV) is an etiological risk factor for a subset of head and neck squamous cell carcinomas. HPV has been proven to be a powerful prognostic biomarker for oropharyngeal cancer, but its role in the larynx has not been explored in depth. Here, we sought to evaluate the prevalence and genotype distribution of HPV in patients with laryngeal squamous cell carcinoma (LSCC) in northeast China. Methods: HPV DNA in specimens from 211 patients diagnosed with LSCC was analyzed by the polymerase chain reaction and in situ hybridization, and p16 overexpression was evaluated by immunohistochemistry. p16 expression was scored positive if strong and diffuse nuclear and cytoplasmic staining was present in > 75% of tumor cells. Results: In this study, infection with HPV and p16 expression were not absolutely consistent. Among all patients, 132 (62.6%) were positive for HPV DNA (HPV+), while 23 (10.9%) were inconsistent for HPV and p16. Multivariate analysis indicated that HPV, but not p16, is an independent prognostic factor for overall survival in LSCC. Overall survival was significantly improved in HPV+ LSCC patients compared with the HPV-negative group (hazard ratio, 0.395; 95% confidence interval, 0.185–0.843; p = 0.016). Among the 132 HPV+ patients, 28 (21.2%) were HPV-16 single infection. Conclusion: This study indicates that HPV DNA is a more reliable surrogate marker than p16 for the prediction of survival in patients with LSCC.